Suspended PHASE2 INTERVENTIONAL 2-arm NCT02059785

Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke

Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke---Randomized, Double-blind, Placebo-controlled, Multicenter Study

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Ischemic Stroke

Interventions Pinocembrin for Injection

Updated 5 times since 2017 Last updated: Jun 16, 2016 Started: Jun 30, 2013 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

This trial was suspended. No reason was provided.

This PHASE2 trial investigates Ischemic Stroke and is currently suspended. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE2
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE2
Jan 2017 — Jun 2018 [monthly]

Suspended PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China